ir.nektar.comAbout Us | Nektar Therapeutics

Skip to main navigation SEARCH MEDIA CAREERS CONTACT Our Company Our Story Our Leadership Our Board of Directors Our Partners Locations Contact Our Pipeline ASCO Virtual Booth R&D Pipeline Onzeald ™ (etirinotecan pegol) Dapirolizumab Pegol (Anti-CD40L) Bempegaldesleukin (NKTR-214) NKTR-358 NKTR-262 NKTR-255 Clinical Trials Expanded Access Investigator Sponsored Research Our Medicines U.S. Medicines Marketed by Our Partners EU Medicines Marketed by Our Partners Investigational Medicines Our Science Research Platform Scientific & Clinical Data Presentations Scientific & Medical Events Investors Investor Relations About Us Press Releases Investor Events Stock Information Historic Stock Lookup Analyst Coverage Financials & Filings SEC Filings Corporate Governance Contact IR Email Alerts Media Media Room Video Gallery Image Gallery Careers Overview Life at Nektar Search Jobs Benefits at Nektar Benefits at San Francisco, California Benefits at Huntsville, Alabama Benefits at Hyderabad, India Information for Recruiters About Us We are a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. We build on a chemistry platform that was invented in our labs along with our scientific expertise to focus on developing unique and more precise medicines. Our success is rooted in four key elements: Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We also have a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies. Our track record reflected by a portfolio of successful approved medicines which are emanated from our chemistry platform and are made available globally by our pharmaceutical partners Our unique research and development pipeline of new investigational medicines in cancer and immunology Our proprietary and proven science approach that fuels our discovery efforts Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We also have a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies. News Jun 04, 2020 Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) May 29, 2020 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020) May 22, 2020 Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal May 07, 2020 Nektar Therapeutics Reports First Quarter 2020 Financial Results Latest and Upcoming Investor Events Webcast Conference Call for Analysts at EULAR Jun 5, 2020 at 11:00 AM EDT Contact Nektar Investor Relations Vivian Wu Manager, Competitive Intelligence & Investor Relations 628-895-0661 Email Transfer Agent and Stockholder Services Computershare Shareholder Services P.O. Box 43006 Providence, RI 02940-3006 (877) 290-2261 (201) 680-6578 www.computershare.com/investor Investor Relations About Us Press Releases Investor Events Stock Information Historic Stock Lookup Analyst Coverage Financials & Filings SEC Filings Corporate Governance Contact IR Email Alerts QUICK LINKS Our Company Our Pipeline Our Medicines Our Science Investors Media Careers Contact Privacy Terms of Use CONNECT LOCATIONS San Francisco, CA Huntsville, AL Hyderabad, India Copyright Nektar © 2020...